Rigel Pharmaceuticals Inc Quick Ratio (RIGL) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Rigel Pharmaceuticals Inc  (NASDAQ: RIGL)

Rigel Pharmaceuticals Inc's Quick Ratio

RIGL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Rigel Pharmaceuticals Inc's Cash & cash equivalent grew by 53.63 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Rigel Pharmaceuticals Inc's Quick Ratio to 4.35, Quick Ratio remained below Rigel Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 196 other companies have achieved higher Quick Ratio than Rigel Pharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 762 to 765.

Explain Quick Ratio?
How much Cash & cash equivalents RIGL´s has?
What are RIGL´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RIGL Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -40.14 % 34.31 % 37.68 % 73.81 % 47.72 %
Y / Y Cash & cash equivalent Change 107.92 % 90.25 % 100.4 % 124.41 % 120.72 %
Quick Ratio MRQ 4.35 1.64 1.56 1.45 1.25
RIGL's Total Ranking # 765 # 762 # 659 # 1164 # 373
Seq. Current Liabilities Change -42.05 % -9.82 % 5.12 % 8.96 % 30.03 %
Seq. Cash & cash equivalent Change 53.63 % -5.34 % 12.99 % 26.54 % 40.57 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 197
Healthcare Sector # 327
Overall Market # 765


Quick Ratio Statistics
High Average Low
53.33 9.01 0.68
(Jun 30 2011)   (Mar 31 2024)




Financial Statements
Rigel Pharmaceuticals Inc's Current Liabilities $ 52 Millions Visit RIGL's Balance sheet
Rigel Pharmaceuticals Inc's Cash & cash equivalent $ 225 Millions Visit RIGL's Balance sheet
Source of RIGL's Sales Visit RIGL's Sales by Geography


Cumulative Rigel Pharmaceuticals Inc's Quick Ratio

RIGL's Quick Ratio for the trailling 12 Months

RIGL Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 19.79 % 46.93 % 34.33 % 46.75 % 32.01 %
Y / Y Cash & cash equivalent TTM Growth 105.03 % 106.76 % 101.43 % 42.92 % 15.24 %
Quick Ratio TTM 1.98 1.48 1.38 1.25 1.16
Total Ranking TTM # 3938 # 2966 # 1878 # 3190 # 1009
Seq. Current Liabilities TTM Growth -9.41 % 6.59 % 8.49 % 14.33 % 11.12 %
Seq. Cash & cash equivalent TTM Growth 21.38 % 14.57 % 19.41 % 23.47 % 22.4 %

Quick ratio ranking by company, industry and sector >> Back to RIGL Financial Strength Comparisons >> Go to Compare RIGL Quick Ratio to its Competitors

On the trailing twelve months basis RIGL Cash & cash equivalent more than doubled by 107.92 % in Q2 2026 year on year, while Current Liabilities plummeted to $52 millions, this led to increase in in Rigel Pharmaceuticals Inc's Quick Ratio to 1.98, Quick Ratio remained below RIGL average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Rigel Pharmaceuticals Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2966 to 3938.

Explain Quick Ratio?
How much Cash & cash equivalents RIGL´s has?
What are RIGL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 433
Healthcare Sector # 887
Within the Market # 3938


trailing twelve months Quick Ratio Statistics
High Average Low
25.47 5.04 0.95
(Mar 31 2014)   (Sep 30 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Amylyx Pharmaceuticals Inc   11.86 $ 250.760  Millions$ 21.150  Millions
Moonlake Immunotherapeutics  11.83 $ 537.000  Millions$ 45.392  Millions
Eledon Pharmaceuticals Inc   11.77 $ 170.753  Millions$ 14.503  Millions
Tyra Biosciences Inc   11.76 $ 354.060  Millions$ 30.106  Millions
Opus Genetics Inc   11.69 $ 88.912  Millions$ 7.605  Millions
Aardvark Therapeutics Inc   11.57 $ 73.921  Millions$ 6.387  Millions
Dyne Therapeutics Inc   11.51 $ 898.475  Millions$ 78.029  Millions
Evommune Inc   11.50 $ 201.014  Millions$ 17.487  Millions
Bicara Therapeutics Inc   11.44 $ 497.259  Millions$ 43.475  Millions
Lipocine Inc   11.25 $ 23.267  Millions$ 2.068  Millions
Xenon Pharmaceuticals Inc   10.85 $ 930.686  Millions$ 85.795  Millions
Bicycle Therapeutics Plc  10.71 $ 510.052  Millions$ 47.635  Millions
Entrada Therapeutics Inc   10.44 $ 223.112  Millions$ 21.371  Millions
Vera Therapeutics Inc   10.33 $ 499.161  Millions$ 48.321  Millions
Ideaya Biosciences Inc   10.03 $ 828.955  Millions$ 82.677  Millions
Gri Bio Inc   9.95 $ 10.947  Millions$ 1.100  Millions
Renovorx Inc   9.86 $ 18.579  Millions$ 1.884  Millions
Savara Inc   9.83 $ 173.034  Millions$ 17.599  Millions
Bullfrog Ai Holdings Inc   9.79 $ 6.918  Millions$ 0.707  Millions
Enveric Biosciences Inc   9.63 $ 8.296  Millions$ 0.861  Millions
Pliant Therapeutics Inc   9.62 $ 158.500  Millions$ 16.484  Millions
Rezolute Inc   9.44 $ 107.801  Millions$ 11.418  Millions
Crescent Biopharma Inc   9.26 $ 171.593  Millions$ 18.537  Millions
Marker Therapeutics inc   9.10 $ 22.031  Millions$ 2.420  Millions
Synlogic Inc   9.03 $ 13.200  Millions$ 1.461  Millions
Spruce Biosciences Inc   8.78 $ 96.300  Millions$ 10.963  Millions
Newamsterdam Pharma Company N v   8.69 $ 633.854  Millions$ 72.974  Millions
Medicinova Inc   8.58 $ 25.416  Millions$ 2.961  Millions
Lixte Biotechnology Holdings Inc   8.45 $ 12.670  Millions$ 1.500  Millions
Atrium Therapeutics Inc   8.38 $ 264.135  Millions$ 31.508  Millions

Date modified: 2026-09-26T07:14:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.